<p>結構治療公司（Structure Therapeutics Inc.）贊助的美國存托股票（NASDAQ:GPCR - 獲取免費報告）目前獲得了 14 家覆蓋該股票的券商一致推薦的 “適度買入” 評級，MarketBeat 報道稱。兩名研究分析師給予該股票賣出評級，十一名給予買入評級，一名給予強烈買入評級。在過去一年中，給予該股票評級的券商的平均 12 個月目標價為 99.1111 美元。</p>
<p>獲取 <strong>結構治療</strong> 的提醒：</p>
<ul>
<li>羅氏能否在減肥市場挑戰禮來和諾和諾德？</li>
</ul>
<p>一些股票研究分析師最近對 GPCR 股票進行了評估。HC Wainwright 在 12 月 19 日的報告中將結構治療的目標價從 60.00 美元上調至 90.00 美元，並給予該公司 “買入” 評級。Lifesci Capital 在 9 月 8 日的報告中將結構治療的股票升級為 “強烈買入” 評級。花旗集團在 12 月 12 日的報告中重申了對結構治療股票的 “跑贏大盤” 評級。Piper Sandler 在 10 月 28 日的報告中重新發布了對結構治療股票的 “增持” 評級。最後，Zacks Research 在 10 月 17 日的研究報告中將結構治療的評級從 “持有” 下調至 “強烈賣出”。</p>
<p><strong>查看我們對結構治療的最新分析</strong></p>
<h2>結構治療股票下跌 1.9%</h2>
<ul>
<li>諾和諾德的挫折不會持續：一款改變遊戲規則的藥物出現</li>
</ul>
<p>GPCR 股票在週四開盤價為 69.95 美元。該公司的 50 日移動平均線為 41.18 美元，200 日移動平均線為 28.21 美元。結構治療的 1 年最低價為 13.22 美元，1 年最高價為 94.90 美元。該公司的市值為 42.4 億美元，市盈率為-57.33，貝塔值為-1.64。</p>
<p>結構治療（NASDAQ:GPCR - 獲取免費報告）最近在 11 月 6 日發佈了其財報。公司報告季度每股收益（EPS）為（0.37）美元，低於市場共識預期的（0.36）美元，差距為（0.01）美元。賣方分析師預測結構治療在本年度將發佈-0.82 美元的每股收益。</p>
<h2>結構治療的機構交易</h2>
<ul>
<li>Altimmune 股票：它的 GLP-1 藥物是下一個 Ozempic 殺手嗎？</li>
</ul>
<p>一些對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Invesco Ltd.在第一季度將其在結構治療的持倉增加了 6.1%。Invesco Ltd.目前擁有 394,386 股該公司的股票，價值 6,827,000 美元，此前在上個季度增持了 22,619 股。Quantbot Technologies LP 在第一季度獲得了結構治療的新股份，價值約 249,000 美元。Jump Financial LLC 在第一季度購買了結構治療的新股份，價值 532,000 美元。Trexquant Investment LP 在第一季度將其在結構治療的持倉增加了 127.6%。Trexquant Investment LP 目前擁有 120,340 股該公司的股票，價值 2,083,000 美元，此前在上個季度增持了 67,464 股。最後，DAFNA Capital Management LLC 在第一季度將其在結構治療的持倉增加了 66.2%。DAFNA Capital Management LLC 目前擁有 59,000 股該公司的股票，價值 1,021,000 美元，此前在上個季度增持了 23,500 股。91.78% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>結構治療公司簡介</h2>
<p>（獲取免費報告）</p>
<p>結構治療（NASDAQ: GPCR）是一家臨牀階段的生物技術公司，專注於發現和開發針對 G 蛋白偶聯受體（GPCRs）的口服小分子療法。該公司利用結構生物學、計算化學和藥物化學的進展，科學平台旨在優化結合相互作用和藥代動力學特性，目標是提供創新的代謝和炎症疾病治療方案。</p>
<p>該公司的產品管線包括多個處於臨牀前和臨牀開發不同階段的項目。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比結構治療更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI 吧，這將是下一個重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在結構治療嗎？</h2>
<p>在考慮結構治療之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而結構治療並不在名單上。</p>
<p>雖然結構治療目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GPCR

<p>Structure Therapeutics Inc.（納斯達克代碼：GPCR）獲得了 14 家券商的共識 “適度買入” 推薦。兩位分析師給予 “賣出” 評級，十一位分析師給予 “買入” 評級，一位分析師給予 “強烈買入” 評級。12 個月的平均目標價為 99.11 美元。最近的分析師行動包括 HC Wainwright 將其目標價上調至 90 美元，以及 Lifesci Capital 升級至 “強烈買入”。該股票的 1 年價格區間為 13.22 美元至 94.90 美元，市值為 42.4 億美元</p>

<p>Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of &#34;Moderate Buy&#34; by the fourteen brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $99.1111.</p>
<div class="lb-trans"><p>結構治療公司（Structure Therapeutics Inc.）贊助的美國存托股票（NASDAQ:GPCR - 獲取免費報告）目前獲得了 14 家覆蓋該股票的券商一致推薦的 “適度買入” 評級，MarketBeat 報道稱。兩名研究分析師給予該股票賣出評級，十一名給予買入評級，一名給予強烈買入評級。在過去一年中，給予該股票評級的券商的平均 12 個月目標價為 99.1111 美元。</p>
</div><p>Get <strong>Structure Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>結構治療</strong> 的提醒：</p>
</div><ul>
<li>Can Roche Challenge Lilly and Novo in the Weight Loss Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>羅氏能否在減肥市場挑戰禮來和諾和諾德？</li>
</ul>
</div><p>A number of equities research analysts recently weighed in on GPCR shares. HC Wainwright raised their price target on Structure Therapeutics from $60.00 to $90.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 19th. Lifesci Capital upgraded shares of Structure Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, September 8th. Citigroup restated an &#34;outperform&#34; rating on shares of Structure Therapeutics in a report on Friday, December 12th. Piper Sandler reissued an &#34;overweight&#34; rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Finally, Zacks Research lowered Structure Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Friday, October 17th.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 GPCR 股票進行了評估。HC Wainwright 在 12 月 19 日的報告中將結構治療的目標價從 60.00 美元上調至 90.00 美元，並給予該公司 “買入” 評級。Lifesci Capital 在 9 月 8 日的報告中將結構治療的股票升級為 “強烈買入” 評級。花旗集團在 12 月 12 日的報告中重申了對結構治療股票的 “跑贏大盤” 評級。Piper Sandler 在 10 月 28 日的報告中重新發布了對結構治療股票的 “增持” 評級。最後，Zacks Research 在 10 月 17 日的研究報告中將結構治療的評級從 “持有” 下調至 “強烈賣出”。</p>
</div><p><strong>Check Out Our Latest Analysis on Structure Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對結構治療的最新分析</strong></p>
</div><h2>Structure Therapeutics Trading Down 1.9%</h2>
<div class="lb-trans"><h2>結構治療股票下跌 1.9%</h2>
</div><ul>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德的挫折不會持續：一款改變遊戲規則的藥物出現</li>
</ul>
</div><p>GPCR stock opened at $69.95 on Thursday. The business's 50 day moving average is $41.18 and its 200-day moving average is $28.21. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $4.24 billion, a P/E ratio of -57.33 and a beta of -1.64.</p>
<div class="lb-trans"><p>GPCR 股票在週四開盤價為 69.95 美元。該公司的 50 日移動平均線為 41.18 美元，200 日移動平均線為 28.21 美元。結構治療的 1 年最低價為 13.22 美元，1 年最高價為 94.90 美元。該公司的市值為 42.4 億美元，市盈率為-57.33，貝塔值為-1.64。</p>
</div><p>Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.</p>
<div class="lb-trans"><p>結構治療（NASDAQ:GPCR - 獲取免費報告）最近在 11 月 6 日發佈了其財報。公司報告季度每股收益（EPS）為（0.37）美元，低於市場共識預期的（0.36）美元，差距為（0.01）美元。賣方分析師預測結構治療在本年度將發佈-0.82 美元的每股收益。</p>
</div><h2>Institutional Trading of Structure Therapeutics</h2>
<div class="lb-trans"><h2>結構治療的機構交易</h2>
</div><ul>
<li>Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Altimmune 股票：它的 GLP-1 藥物是下一個 Ozempic 殺手嗎？</li>
</ul>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of Structure Therapeutics by 6.1% in the first quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after acquiring an additional 22,619 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Structure Therapeutics during the first quarter worth approximately $249,000. Jump Financial LLC bought a new stake in Structure Therapeutics in the 1st quarter valued at $532,000. Trexquant Investment LP grew its stake in shares of Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after acquiring an additional 67,464 shares in the last quarter. Finally, DAFNA Capital Management LLC grew its position in shares of Structure Therapeutics by 66.2% during the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after purchasing an additional 23,500 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Invesco Ltd.在第一季度將其在結構治療的持倉增加了 6.1%。Invesco Ltd.目前擁有 394,386 股該公司的股票，價值 6,827,000 美元，此前在上個季度增持了 22,619 股。Quantbot Technologies LP 在第一季度獲得了結構治療的新股份，價值約 249,000 美元。Jump Financial LLC 在第一季度購買了結構治療的新股份，價值 532,000 美元。Trexquant Investment LP 在第一季度將其在結構治療的持倉增加了 127.6%。Trexquant Investment LP 目前擁有 120,340 股該公司的股票，價值 2,083,000 美元，此前在上個季度增持了 67,464 股。最後，DAFNA Capital Management LLC 在第一季度將其在結構治療的持倉增加了 66.2%。DAFNA Capital Management LLC 目前擁有 59,000 股該公司的股票，價值 1,021,000 美元，此前在上個季度增持了 23,500 股。91.78% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>Structure Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>結構治療公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.</p>
<div class="lb-trans"><p>結構治療（NASDAQ: GPCR）是一家臨牀階段的生物技術公司，專注於發現和開發針對 G 蛋白偶聯受體（GPCRs）的口服小分子療法。該公司利用結構生物學、計算化學和藥物化學的進展，科學平台旨在優化結合相互作用和藥代動力學特性，目標是提供創新的代謝和炎症疾病治療方案。</p>
</div><p>The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於臨牀前和臨牀開發不同階段的項目。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Structure Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比結構治療更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>資本利得税是否可以扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI 吧，這將是下一個重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GPCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Structure Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在結構治療嗎？</h2>
</div><p>Before you consider Structure Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮結構治療之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而結構治療並不在名單上。</p>
</div><p>While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然結構治療目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Structure Therapeutics Inc. 贊助的美國存託憑證（NASDAQ:GPCR）被券商一致推薦為 “適度買入”